• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Osimertinib in combination with bevacizumab in -Mutated NSCLC with leptomeningeal metastases.

作者信息

Jiang Tao, Xu Xiaobo, Chen Xiaojuan, Ding Ning, Hu Qin, Zhou Caicun, Hu Jie

机构信息

Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.

Department of Pulmonary Medicine, Shanghai Respiratory Research Institute, Zhongshan Hospital Affiliated to Fudan University, Shanghai, China.

出版信息

Transl Lung Cancer Res. 2020 Dec;9(6):2514-2517. doi: 10.21037/tlcr-20-984.

DOI:10.21037/tlcr-20-984
PMID:33489813
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7815344/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12dc/7815344/b532da9ee93d/tlcr-09-06-2514-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12dc/7815344/b532da9ee93d/tlcr-09-06-2514-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12dc/7815344/b532da9ee93d/tlcr-09-06-2514-f1.jpg

相似文献

1
Osimertinib in combination with bevacizumab in -Mutated NSCLC with leptomeningeal metastases.奥希替尼联合贝伐单抗治疗伴有软脑膜转移的EGFR突变型非小细胞肺癌
Transl Lung Cancer Res. 2020 Dec;9(6):2514-2517. doi: 10.21037/tlcr-20-984.
2
Management of CNS metastases in patients with EGFR mutation-positive NSCLC.表皮生长因子受体（EGFR）突变阳性非小细胞肺癌（NSCLC）患者中枢神经系统转移的管理
Indian J Cancer. 2019 Nov;56(Supplement):S31-S37. doi: 10.4103/ijc.IJC_455_19.
3
Treatment Response To Osimertinib In -Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series.奥希替尼治疗非小细胞肺癌伴EGFR突变软脑膜转移的疗效：病例系列
Onco Targets Ther. 2019 Sep 20;12:7785-7790. doi: 10.2147/OTT.S199452. eCollection 2019.
4
Complete Remission of Multiple Brain Metastases in a Patient with -Mutated Non-Small-Cell Lung Cancer Treated with First-Line Osimertinib without Radiotherapy.一名携带 - 突变的非小细胞肺癌患者在一线使用奥希替尼治疗且未接受放疗的情况下多发脑转移完全缓解。
Case Rep Oncol Med. 2020 Mar 19;2020:9076168. doi: 10.1155/2020/9076168. eCollection 2020.
5
Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.EGFR 酪氨酸激酶抑制剂在难治性脑膜转移 NSCLC 中的活性。
J Thorac Oncol. 2019 Aug;14(8):1400-1407. doi: 10.1016/j.jtho.2019.05.007. Epub 2019 May 18.
6
Three Novel Mutations (750_758del, I759S, T751_I759delinsS) in One Patient with Metastatic Non-Small Cell Lung Cancer Responding to Osimertinib: A Case Report.一例对奥希替尼有反应的转移性非小细胞肺癌患者的三种新突变（750_758del、I759S、T751_I759delinsS）：病例报告
Onco Targets Ther. 2020 Aug 10;13:7941-7948. doi: 10.2147/OTT.S259616. eCollection 2020.
7
Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and -C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report.奥希替尼、贝伐单抗和布加替尼联合治疗携带L858R、T790M和-C797S三重EGFR突变的肺腺癌：一例报告
Onco Targets Ther. 2018 Sep 6;11:5545-5550. doi: 10.2147/OTT.S170358. eCollection 2018.
8
Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR.奥希替尼成功治疗伴有表皮生长因子受体（EGFR）T790M突变的肺腺癌软脑膜癌病。
ESMO Open. 2017 Mar 7;2(Suppl 1):e000104. doi: 10.1136/esmoopen-2016-000104. eCollection 2017.
9
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.一线治疗晚期表皮生长因子受体突变型非小细胞肺癌患者的疗效和安全性：系统评价和网络荟萃分析。
BMJ. 2019 Oct 7;367:l5460. doi: 10.1136/bmj.l5460.
10
Erlotinib and bevacizumab combination therapy for afatinib-refractory leptomeningeal carcinomatosis from EGFR-mutated lung cancer.厄洛替尼与贝伐单抗联合治疗EGFR突变型肺癌导致的阿法替尼耐药性软脑膜癌病
Int Cancer Conf J. 2019 Jan 18;8(2):81-85. doi: 10.1007/s13691-019-00358-6. eCollection 2019 Apr.

引用本文的文献

1
A comprehensive comparison of third generation epidermal growth factor receptor tyrosine kinase inhibitors in the treatment efficacy and adverse events: A Bayesian meta-analysis.第三代表皮生长因子受体酪氨酸激酶抑制剂治疗疗效与不良事件的综合比较：一项贝叶斯荟萃分析。
Glob Med Genet. 2025 Jun 15;12(3):100064. doi: 10.1016/j.gmg.2025.100064. eCollection 2025 Sep.
2
Intrathecal pemetrexed chemotherapy combined with systemic therapy in patients with non-small cell lung cancer and leptomeningeal metastases: a retrospective study.鞘内培美曲塞化疗联合全身治疗非小细胞肺癌合并软脑膜转移患者：一项回顾性研究
Front Oncol. 2025 Apr 7;15:1545174. doi: 10.3389/fonc.2025.1545174. eCollection 2025.
3

本文引用的文献

1
Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations.非小细胞肺癌中的脑膜转移：有无驱动基因突变的 NSCLC 的最佳全身治疗策略。
Curr Treat Options Oncol. 2020 Jul 28;21(9):72. doi: 10.1007/s11864-020-00759-3.
2
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced -Mutated Non-small Cell Lung Cancer: A Meta-Analysis.表皮生长因子受体（EGFR）抑制剂联合抗血管生成药物作为晚期EGFR突变非小细胞肺癌患者一线治疗的疗效和安全性：一项荟萃分析
Front Oncol. 2020 Jun 25;10:904. doi: 10.3389/fonc.2020.00904. eCollection 2020.
3
Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysiss.
奥希替尼与经治的非小细胞肺癌软脑膜转移患者预后改善相关：一项系统评价和荟萃分析。
Heliyon. 2024 Apr 17;10(9):e29668. doi: 10.1016/j.heliyon.2024.e29668. eCollection 2024 May 15.
4
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases.奥希替尼治疗后进展的 EGFR 突变型 NSCLC 和脑膜转移的后续治疗。
BMC Med. 2022 May 30;20(1):197. doi: 10.1186/s12916-022-02387-0.
5
Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases.病例报告：奥希替尼序贯奥希替尼联合贝伐单抗治疗，为一名患有新型外显子20插入D770_N771insGT和多发脑转移的肺癌患者制定的个性化治疗策略。
Front Oncol. 2021 Oct 25;11:733276. doi: 10.3389/fonc.2021.733276. eCollection 2021.
6
Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches.实体瘤的软脑膜转移：诊断与分子方法的最新进展
Cancers (Basel). 2021 Jun 9;13(12):2888. doi: 10.3390/cancers13122888.
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status.
奥希替尼改善了不论 T790M 突变状态如何的伴有脑膜转移的 EGFR 突变型 NSCLC 患者的总生存期。
J Thorac Oncol. 2020 Nov;15(11):1758-1766. doi: 10.1016/j.jtho.2020.06.018. Epub 2020 Jul 9.
4
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.一项评估奥希替尼 160mg 治疗经既往 EGFR-TKI 治疗后进展的存在脑转移或软脑膜疾病的、携带 EGFR T790M 突变的非小细胞肺癌患者的 II 期、多中心、两队列研究。
Ann Oncol. 2020 Oct;31(10):1397-1404. doi: 10.1016/j.annonc.2020.06.017. Epub 2020 Jul 5.
5
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.奥希替尼联合贝伐珠单抗治疗 EGFR 突变型转移性非小细胞肺癌患者的无进展生存的影响：一项 1/2 期单组开放标签试验
JAMA Oncol. 2020 Jul 1;6(7):1048-1054. doi: 10.1001/jamaoncol.2020.1260.
6
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.奥希替尼治疗表皮生长因子受体突变阳性非小细胞肺癌伴脑膜转移患者：BLOOM 研究。
J Clin Oncol. 2020 Feb 20;38(6):538-547. doi: 10.1200/JCO.19.00457. Epub 2019 Dec 6.
7
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
8
EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）联合贝伐珠单抗治疗表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）伴多发脑转移患者，较 EGFR-TKIs 单药治疗有生存获益。
Eur J Cancer. 2019 Nov;121:98-108. doi: 10.1016/j.ejca.2019.08.021. Epub 2019 Sep 27.
9
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.厄洛替尼联合贝伐珠单抗对比厄洛替尼单药治疗表皮生长因子受体阳性的晚期非鳞状非小细胞肺癌（NEJ026）：一项开放标签、随机、多中心、III 期临床试验的期中分析。
Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8.
10
A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.AME肺癌协作组关于奥希替尼在非小细胞肺癌中作用的共识。
J Thorac Dis. 2018 Jul;10(7):3909-3921. doi: 10.21037/jtd.2018.07.61.